Alexander Bisignano is responsible for setting strategy and vision for Phosphorus, a full-stack genomics as a service company. Before Phosphorus, Alex co-founded Recombine, a clinical genetic testing company, which was acquired by CooperSurgical in May of 2016 for $85M. At Phosphorus and Recombine Alex developed novel genotyping and next-generation sequencing assays for clinical genetics. His work has been presented at the American Society for Reproductive Medicine, the European Society for Human Reproduction and Embryology, the National Lipid Association Annual Meeting, the American Society of Human Genetics and a number of other scientific programs. Alex has also appeared on Fox Business and Bloomberg TV as an expert in the genetic testing market. Alex received his A.B. in molecular biology from Princeton University and is a member of Sigma Xi, the Scientific Research Society.
Preimplantation Genetic Testing Beyond Recessive Disease
Testing for aneuploidy and recessive monogenic disease in human embryos is a well-practiced application of Next-Generation Sequencing. However, as genomics has become more prevalent across various parts of society, early demand is emerging to screen embryos for later-onset, dominant diseases. This session focuses on the technical, clinical and ethical considerations in selecting human embryos based on the analysis of late-onset.
Researchers have long been recognizing the uniqueness of women’s health and the substantial effect on clinical practice, acknowledging the increasing appreciation of the importance of multidisciplinary approaches to health and disease. In every organ system, there are diseases that are unique to women, more common in women than in men, or characterized by differences in disease course in women compared with men. This session will include the effect of women’s health on the following topics: